Related Experiment Video

Updated: May 24, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

mTOR kinase inhibitors as a treatment strategy in hematological malignancies

Olga Grzybowska-Izydorczyk1, Piotr Smolewski

  • 1Department of Experimental Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.

Future Medicinal Chemistry
|March 16, 2012
PubMed

Insights

Targeting the mammalian target of rapamycin (mTOR) pathway with inhibitors shows promise for treating hematological malignancies like lymphomas and leukemias. Newer mTOR inhibitors are currently under investigation for their anti-tumor efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mammalian target of rapamycin (mTOR) pathway regulates cell growth and proliferation.
  • Aberrant mTOR pathway activation is implicated in various human malignancies.
  • mTOR inhibitors, starting with rapamycin (sirolimus), offer potential anti-cancer therapeutic strategies.

Purpose of the Study:

  • To review the efficacy of mTOR inhibitors in treating hematological malignancies.
  • To discuss the development and clinical application of rapamycin analogues (rapalogues).
  • To highlight the potential of mTOR pathway inhibition as an anti-tumor treatment.

Main Methods:

  • Review of preclinical experiments and clinical trials involving mTOR inhibitors.
  • Analysis of monotherapy and combination treatments with cytotoxic agents.
  • Assessment of rapamycin analogues (everolimus, temsirolimus, deforolimus) and newer generation inhibitors.

Main Results:

  • Clinical trials indicate that mTOR pathway inhibition is a promising anti-tumor strategy in lymphomas and leukemias.
  • Rapalogues have been tested in monotherapy and combination regimens.
  • Second-generation mTOR inhibitors are undergoing preclinical and early-phase clinical evaluation.

Conclusions:

  • Inhibition of the mTOR pathway represents a highly promising therapeutic strategy for hematological malignancies.
  • Rapalogues have demonstrated potential in treating various lymphomas and leukemias.
  • Ongoing research into novel mTOR inhibitors may yield more effective anti-cancer treatments.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...